Thrombin generation is associated with extracellular vesicle and leukocyte lipid membranes in acute coronary syndrome - Protty, Majd B; Tyrrell, Victoria J; Allen-Redpath, Keith; Soyama, Shin; Hajeyah, Ali A; Costa, Daniela; Choudhury, Anirban; Mitra, Rito; Yaqoob, Parveen; Jenkins, P Vince; Yousef, Zaheer; Collins, Peter W; et al. (medRxiv, 2023)
Background Acute coronary syndrome (ACS) is caused by arterial thrombosis and is associated with sustained activation of coagulation. Clotting requires interactions of coagulation factors with aminophospholipids (aPL): phosphatidylserine (PS) and phosphatidylethanolamine (PE) on membrane surfaces. The aPL composition of circulating membranes in coronary disease has not been characterized. Furthermore, the contribution of external-facing aPL to elevated thrombotic risk in ACS is unknown.Methods and results Thrombin generation was measured on platelet, leukocyte and extracellular vesicles (EV) from patients with ACS (n = 24), stable coronary artery disease (CAD, n = 18), risk factor positive (RF, n = 23) and healthy controls (HC, n = 24). The aPL composition on the surface of EV, platelets and leukocytes was determined using lipidomics. Leukocytes, platelets and EV externalized PE- and PS-containing fatty acids ranging from C16:0-20:4. These included both diacyl and plasmalogen forms, with significant increases stimulated by agonist activation. Thrombin generation on the surface of EV and leukocytes was higher in ACS than HC. Also, thrombin generation was higher for EV from CAD and RF, than HC. EV counts were higher in CAD and ACS compared with HC. Thrombin generation correlated positively with plasma EV counts and membrane surface area.Conclusion The aPL membrane of EV and leukocytes may contribute to the activation of coagulation in CAD and ACS. Targeting EV formation/clearance and the aPL surface of EV and leukocyte membranes represents a novel anti-thrombotic target in CAD and ACS.Condensed abstract Acute coronary syndrome (ACS) is associated with sustained activation of coagulation, requiring procoagulant aminophospholipids (aPL). However, the aPL composition of circulating membranes and their contribution to thrombotic risk in ACS is undetermined. Lipidomics demonstrated that leukocytes, platelets and extracellular vesicles (EV) externalized aPL-containing fatty acids ranging from C16:0-20:4. Thrombin generation on the surface of EV and leukocytes was higher in ACS patients than healthy controls (HC). EV counts were higher in ACS compared with HC and correlated positively with thrombin generation. In summary, aPL in the outer membranes of EV and leukocytes may contribute to elevated thrombotic risk in ACS.What is new?The aPL profile of platelets, leukocytes and EV in patients with ACS, CAD, RF and HC is defined for the first-time using lipidomics.Thrombin generation on the surface of unstimulated leukocytes, is elevated in patients with ACS compared with HC.Thrombin generation on the surface of EV is elevated in patients with ACS, CAD and RF compared with HC.EV counts in patients with ACS/CAD/RF were elevated compared with HC and correlate positively with thrombin generation.What are the clinical implications?The membranes of EV and leukocytes may contribute to the activation of coagulation in ACS.The aPL in EV and leukocyte membranes represent a novel target for reducing thrombotic risk in ACS.Targeting EV formation/clearance could reduce thrombotic risk in CAD and ACS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wellcome Trust (GW4-CAT fellowship to M.P - 216278/Z/19/Z) and the British Heart Foundation (Programme grant to P.C and V.B.O - RG/F/20/110020). DB is in receipt of a HCRW NHS Research Time Award. VJT was supported in part by the Welsh Government/EU Ser Cymru Programme. AAH is supported by a grant from Kuwait University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was from Health and Care Research Wales (HCRW, IRAS 243701; REC reference 18/YH/0502).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors